Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotech advancing novel therapies for fibro-inflammatory diseases. This news hub provides investors and researchers with essential updates on nebokitug (CM-101), the company's lead monoclonal antibody targeting CCL24 in conditions like primary sclerosing cholangitis (PSC) and systemic sclerosis.
Access timely reports on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes verified updates from Phase 2/3 trials, FDA/EMA designations, and scientific conference presentations. Key focus areas span biomarker validation, trial enrollment status, and intellectual property developments.
This resource serves as your central source for tracking Chemomab's progress in addressing high-need rare diseases. Bookmark this page for direct access to primary documents including SEC filings, peer-reviewed data publications, and official press releases. Check regularly for updates on the upcoming Phase 3 PSC trial and expansion into new fibrotic disease indications.
Chemomab Therapeutics (CMMB) reported its Q1 2022 financial results, revealing a net loss of $5.1 million, or $0.02 per share, compared to a $1.7 million loss in Q1 2021. Cash and equivalents decreased to $57.5 million from $61.2 million at year-end 2021. R&D expenses rose significantly to $2.7 million, while G&A expenses jumped to $2.6 million, influenced by stock-based compensation. The company is progressing in its CM-101 clinical trial for fibrotic diseases, expanding into new regions, with an interim analysis expected later this year.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) will announce its first quarter 2022 financial results and provide a business update on May 12, 2022, during a conference call at 8:00 am ET. The call will review performance, recent events, and feature a live Q&A session. Chemomab focuses on developing therapeutics for fibrotic and inflammatory diseases, with its CM-101 monoclonal antibody currently in two Phase 2 trials for severe conditions affecting the liver and systemic sclerosis. For further details, visit chemomab.com.
Chemomab Therapeutics Ltd (Nasdaq: CMMB), a clinical-stage biotechnology company, will participate in the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 29, 2022. Co-founder and Chief Scientific Officer Adi Mor will be a panelist. The discussion will focus on 'Platforms and Pipelines in a Product', highlighting potential applications across various rare diseases. Chemomab specializes in innovative therapies for fibrotic and inflammatory diseases, with their lead product, CM-101, in Phase 2 trials for multiple conditions.
Chemomab Therapeutics (Nasdaq: CMMB) presented significant findings regarding its lead candidate, CM-101, at recent conferences in Israel. Data indicated that CCL24 levels were elevated in patients with diffuse cutaneous systemic sclerosis (dcSSc), correlating with disease activity and poor prognosis. The company plans to initiate a Phase 2 trial for CM-101 later this year, aiming to target CCL24 to address unmet needs in systemic sclerosis, a serious autoimmune disease.
Chemomab Therapeutics, Ltd. (CMMB) reported its fourth quarter and full-year 2021 financial results, showcasing a cash position of $61.2 million compared to $11.8 million in 2020. R&D expenses rose to $2.4 million for Q4 and $6.3 million for the year, while G&A expenses increased to $2.6 million for Q4 and $6.0 million for the year. The net loss was $5.0 million for Q4, totaling $12.5 million for 2021. Significant clinical program revisions were announced, aimed at optimizing the development of CM-101, including expanded trials for PSC and SSc, with more data readouts expected over the next 24 months.
Chemomab Therapeutics (CMMB) will announce its fourth quarter and full year 2021 financial results on March 9, 2022. The company focuses on developing therapeutics for fibrotic and inflammatory diseases. A conference call will be held at 8:00 a.m. Eastern Time to discuss performance and upcoming events. Chemomab's key product, CM-101, is currently undergoing two Phase 2 trials with a third set to start in early 2022. This innovative approach targets the CCL24 protein, which is central to fibrosis and inflammation.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company, announced it will present at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 9:00 am ET. The company focuses on innovative therapeutics for fibrotic and inflammatory diseases, highlighting its monoclonal antibody CM-101, designed to block the soluble protein CCL24, which is linked to these conditions. CM-101 is currently undergoing two Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a third trial in systemic sclerosis anticipated to start in early 2022.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced the appointment of Jack Lawler as Vice President of Global Clinical Development Operations, enhancing its clinical development leadership. Lawler brings over 22 years of experience in drug development, previously contributing to eight approved pharmaceuticals. Chemomab has also expanded its facilities in Tel Aviv to support anticipated growth. The company focuses on developing CM-101, a monoclonal antibody aimed at addressing serious fibrotic and inflammatory diseases, currently in two Phase 2 trials.
Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) announced participation in two key virtual events: the LifeSci Partners 11th Annual Corporate Access Event from January 5-7, 2022, featuring 1-on-1 meetings, and the H.C. Wainwright BioConnect Conference from January 10-13, 2022, offering an on-demand corporate overview webcast. Chemomab focuses on therapeutics for fibrotic and inflammatory diseases, with its lead candidate, CM-101, in Phase 2 trials targeting multiple severe conditions. For event registration and additional details, visit Chemomab's website.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) has announced that CEO Dale R. Pfost will take on the role of Chairman, pending shareholder approval expected in February 2022. Stephen Squinto will step down from his role as Chairman and director on December 19, 2021. Dr. Pfost expressed excitement for the company's Phase 2 clinical programs in liver fibrosis and systemic sclerosis. Chemomab is developing CM-101, a monoclonal antibody targeting CCL24, currently undergoing clinical trials for severe fibrotic and inflammatory diseases.
FAQ
What is the current stock price of Chemomab Therapeutics (CMMB)?
What is the market cap of Chemomab Therapeutics (CMMB)?
